ACTAVIA LIFE SCIENCES, INC. (RASP) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
5 PENN PLAZA, 19TH FLOOR, #1954 NEW YORK, NY 10001 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2024 MRQ | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 75 | 39 | 11 | 14 | 50 | 43 | |||
| Cash and cash equivalent | 75 | 39 | 11 | 14 | 50 | 43 | |||
| Receivables | 1 | 14 | 238 | ||||||
| Other undisclosed current assets | 34 | 18 | 7 | 67 | |||||
| Total current assets: | 75 | 39 | 45 | 33 | 72 | 347 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 0 | 2 | 5 | ||||||
| Intangible assets, net (including goodwill) | 2,959 | 2,959 | |||||||
| Goodwill | 2,723 | 2,723 | |||||||
| Intangible assets, net (excluding goodwill) | 236 | 236 | |||||||
| Other undisclosed noncurrent assets | 1,913 | 1,913 | |||||||
| Total noncurrent assets: | 0 | 4,874 | 4,878 | ||||||
| Other undisclosed assets | 21 | 46 | |||||||
| TOTAL ASSETS: | 96 | 85 | 45 | 33 | 4,946 | 5,225 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 1,458 | 1,351 | 1,516 | 1,636 | 1,591 | 1,422 | |||
| Accounts payable | 960 | 952 | 864 | 720 | |||||
| Accrued liabilities | 499 | 529 | 616 | 684 | 727 | 702 | |||
| Other undisclosed accounts payable and accrued liabilities | 822 | 900 | |||||||
| Debt | 211 | 107 | 370 | 165 | |||||
| Derivative instruments and hedges, liabilities | 2 | 8 | |||||||
| Due to related parties | ✕ | ✕ | 195 | 561 | 550 | 550 | 550 | ||
| Other undisclosed current liabilities | 380 | 21 | 260 | 265 | 137 | ||||
| Total current liabilities: | 2,052 | 1,682 | 2,707 | 2,350 | 2,405 | 2,109 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 92 | ||||||||
| Long-term debt, excluding current maturities | 92 | ||||||||
| Liabilities, other than long-term debt | 11 | ||||||||
| Deferred tax liabilities, net | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 11 | ||
| Other undisclosed noncurrent liabilities | 3 | ||||||||
| Total noncurrent liabilities: | 92 | 3 | 11 | ||||||
| Other undisclosed liabilities | 357 | ||||||||
| Total liabilities: | 2,052 | 1,774 | 2,707 | 2,708 | 2,409 | 2,120 | |||
| Equity | |||||||||
| Equity, attributable to parent | (1,956) | (1,689) | (2,663) | (2,675) | 2,537 | 3,106 | |||
| Common stock | 772 | 180 | 69 | 69 | 69 | 69 | |||
| Additional paid in capital | 25,936 | 22,352 | 20,712 | 19,915 | 19,780 | 19,412 | |||
| Accumulated deficit | (28,664) | (24,221) | (23,444) | (22,658) | (17,312) | (16,375) | |||
| Total equity: | (1,956) | (1,689) | (2,663) | (2,675) | 2,537 | 3,106 | |||
| TOTAL LIABILITIES AND EQUITY: | 96 | 85 | 45 | 33 | 4,946 | 5,225 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2024 TTM | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Other undisclosed Revenues) | ||||||||
| Operating expenses | (4,238) | 141 | (248) | (5,429) | (915) | (4,070) | ||
| Operating income (loss): | (4,238) | 141 | (248) | (5,429) | (915) | (4,070) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (204) | (828) | 79 | (29) | (4) | |||
| Interest and debt expense | (1) | (2) | 91 | (41) | (28) | |||
| Loss from continuing operations before equity method investments, income taxes: | (4,444) | (689) | (157) | (5,391) | (972) | (4,074) | ||
| Other undisclosed income from continuing operations before income taxes | 41 | 28 | ||||||
| Loss from continuing operations before income taxes: | (4,444) | (689) | (157) | (5,350) | (944) | (4,074) | ||
| Income tax expense (benefit) | 261 | 3 | 8 | (2) | ||||
| Income (loss) from continuing operations: | (4,444) | (689) | 104 | (5,347) | (936) | (4,076) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | 104 | (5,347) | (936) | (4,076) | |
| Other undisclosed net loss | (889) | |||||||
| Net loss: | (4,444) | (689) | (785) | (5,347) | (936) | (4,076) | ||
| Other undisclosed net income attributable to parent | 1 | 2 | ||||||
| Net loss available to common stockholders, diluted: | (4,443) | (687) | (785) | (5,347) | (936) | (4,076) | ||
Comprehensive Income ($ in thousands)
| 3/31/2024 TTM | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (4,444) | (689) | (785) | (5,347) | (936) | (4,076) | ||
| Comprehensive loss, net of tax, attributable to parent: | (4,444) | (689) | (785) | (5,347) | (936) | (4,076) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.